SOLU MEDROL 500 MG

국가: 이스라엘

언어: 영어

출처: Ministry of Health

유효 성분:

METHYLPREDNISOLONE AS SODIUM SUCCINATE

제공처:

PFIZER PFE PHARMACEUTICALS ISRAEL LTD

ATC 코드:

H02AB04

약제 형태:

POWDER FOR SOLUTION FOR INJ/INF

구성:

METHYLPREDNISOLONE AS SODIUM SUCCINATE 62.5 MG/ML

관리 경로:

I.M, I.V

처방전 유형:

Required

Manufactured by:

PFIZER MANUFACTURING BELGIUM NV/SA

치료 그룹:

METHYLPREDNISOLONE

치료 영역:

METHYLPREDNISOLONE

치료 징후:

Solu Medrol is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.

승인 날짜:

2014-05-31

제품 특성 요약

Solu-Medrol LPD CC 240823
Page 1 of 27
2023-0083910, 2022-0082236
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
SOLU-MEDROL
®
40 mg
SOLU-MEDROL
®
125 mg
SOLU-MEDROL
®
500 mg
SOLU-MEDROL
®
1000 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Solu-Medrol 40 mg:
Methylprednisolone (as methylprednisolone sodium succinate) 40 mg/
Act-o-vial.
Solu-Medrol 125 mg:
Methylprednisolone (as methylprednisolone sodium succinate) 125 mg/
Act-o-vial.
Solu-Medrol 500 mg:
Methylprednisolone (as methylprednisolone sodium succinate) 500 mg/
vial.
Excipient with known effect
Solu-Medrol 500 mg contains 58.4 mg of sodium in each vial.
Solu-Medrol 1000 mg:
Methylprednisolone (as methylprednisolone sodium succinate) 1000 mg/
vial.
Excipient with known effect
Solu-Medrol 1 g contains 116.8 mg of sodium in each vial.
For the full list of excipients, see section 6.1.
Solu-Medrol 500 mg & 1000 mg diluent contain Benzyl alcohol
(see Section 4.4 Special warnings
and precautions for use)
.
3.
PHARMACEUTICAL FORM
Powder for solution for injection or infusion
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Methylprednisolone sodium succinate is indicated in_ _the following
conditions:
ENDOCRINE DISORDERS
•
primary or secondary adrenocortical insufficiency (in conjunction with
mineralocorticoids,
where applicable)
•
acute adrenocortical insufficiency (mineralocorticoid supplementation
may be necessary)
Solu-Medrol LPD CC 240823
Page 2 of 27
2023-0083910, 2022-0082236
•
shock secondary to adrenocortical insufficiency, or shock unresponsive
to conventional
therapy when adrenal cortical insufficiency may be present (when
mineralocorticoid activity
is undesirable)_ _
•
preoperatively, or in the event of serious trauma or illness, in
patients with known adrenal
insufficiency or when adrenocortical reserve is doubtful
•
congenital adrenal hyperplasia
•
nonsuppurative thyroiditis
•
hypercalcemia associated with cancer.
RHEUMATIC DISORDERS (as adjunctive therapy for short-term
administration in the management
of